SOURCE: Equity News Circuit

Equity News Circuit

February 06, 2013 08:00 ET

Squawk Box Stocks Reports On: Opexa Therapeutics, Inc. (NASDAQ: OPXA), ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC), Protalix BioTherapeutics, Inc. (NYSE MKT: PLX), Titan Pharmaceuticals Inc. (OTCQB: TTNP).

Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit

NEW YORK, NY--(Marketwire - Feb 6, 2013) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), ImmunoCellular Therapeutics, Ltd. (NYSE MKT: IMUC), Protalix BioTherapeutics, Inc. (NYSE MKT: PLX), Titan Pharmaceuticals Inc. (OTCQB: TTNP).

Opexa Therapeutics, Inc. (OPXA) saw shares advancing 160.33% or $1.94 per share to close at $3.15 on volume of 9,818,403 shares traded during yesterday's trading session. Tuesday morning the company announced the execution of an agreement with Merck Serono, a division of Merck (MKGAY) Darmstadt, Germany, for the development and commercialization of Tcelna (imilecleucel-T), a potential first-in-class personalized T-cell therapy for patients suffering from multiple sclerosis (MS). Will this positive news spark a further rally in the days to come? Find out in our exclusive report at:

ImmunoCellular Therapeutics, Ltd. (IMUC) was another big gainer seeing shares rise 12.44% to close the day at $2.44 on 1,873,134 shares traded. On Monday, the company announced that Andrew Gengos, Chief Executive Officer of ImmunoCellular, will present a corporate overview and business update at the 15th Annual BIO CEO & Investor Conference on Monday, February 11, 2013 at the Waldorf Astoria Hotel in New York City. Will this forward looking event lead to further gains ahead or will the stock finally give up some of it's recent gains? Find out more in our exclusive report at:

Protalix BioTherapeutics, Inc. (PLX) was another stock seeing increased activity during yesterday's trading session. The company saw shares rise 14.74% to close at $6.15 after seeing an intraday high of $6.73 on volume of 7,490,918 shares traded. The company confirmed, in response to inquiries received Tuesday morning and a report appearing in the Israeli press, that the company has engaged Citigroup to assist it in reviewing a broad array of product partnering, technology sharing and other strategic alternatives. There is no assurance that Protalix will undertake any such strategic alternative. Find out if this announcement will lead to a higher stock price or if the stock will give up yesterday's gains in our exclusive report at:

Titan Pharmaceuticals Inc. (TTNP) saw its shares decline 10.48% to close yesterday at $2.22 on volume of 1,462,289 shares traded. The company is developing Probuphine, a proprietary, long-acting form of the opioid dependence drug buprenorphine. Probuphine is implanted just under the skin of the upper arm and provides continuous delivery of drug for six months. The FDA accepted Probuphine for priority review with an approval decision expected on April 30. Titan also expects FDA to convene an advisory panel to review Probuphine, likely in the second half of March. Is the company on track for approval or will investors end up disappointed? Find out our thoughts in our exclusive report at:


Squawk Box Stocks offers its daily stock alerts and market content newsletter to investors looking for timely information available! Our experienced team provides you only the best stock alerts & research reports delivered to your email inbox for FREE. Our track record of providing winning alerts has won us the trust of thousands of investors worldwide. With our dedicated research team & investor database continuing to grow we have become a leading destination for the most profitable opportunities that are available in today's stock market. To receive our FREE, comprehensive newsletter, visit

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Winning Media LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information

  • Contact Information:
    Winning Media LLC
    Email Contact